MONTREAL, May 3, 2005 (PRIMEZONE) -- Viropro, Inc. (OTCBB:VPRO) is pleased to announce the appointment of Dr. Jean-Marie Dupuy to the position of President of its wholly owned subsidiary Viropro Pharma Inc. As the Company pursues its aggressive expansion, Dr. Dupuy will oversee the various activities of Viropro Pharma Inc. from scientific affairs to strategic business development in international markets.
In making this appointment, Viropro Pharma Inc. plans to dramatically accelerate its penetration into international markets thanks to its large portfolio of mature technologies and products in the field of biopharmaceuticals and rapid diagnostic tests. The Company anticipates announcing new strategic alliances as well as product and market agreements in the near future.
Dr. Dupuy held top managing positions at prestigious pharmaceutical institutions. He was previously Vice-President, Medical & Regulatory Affairs at Immuno-designed Molecules Company; Project Director Immunology / Oncology Programs at Wyeth Ayerst; Medical Director at Pasteur Merieux Connaught and Research Director at Inserm. In addition, he was author and co-author of more than 240 scientific and medical articles, books and publications. Prior to joining the pharmaceutical industry, Dr. Dupuy also held many academic positions in prestigious institutions in Canada and France.
Showing his strong enthusiasm, Dr. Dupuy commented: "I am delighted to join this dynamic team and preside over a company that has shown such a thrust for achievements in key markets." He added: "Our objective is to continue to develop solid partnerships on an international level to favourably position the company in areas of the world such as Latin America, Africa and Asia."
About Viropro, Inc.
Viropro, Inc. (OTCBB:VPRO) is establishing a growth portfolio in Life Sciences markets through strategic alliances and revenue-producing acquisitions with the potential for continued shareholder value.
Viropro, Inc.'s Safe Harbor Statement
Except for any historic information contained herein, the matters discussed in this press release contain forward-looking statements that involve risks and uncertainties, which are subject to section 27A of the Securities Act of 1933 and section 21E of the Exchange Act of 1934, and are subject to safe harbor created by these sections. Any statements that express or involve discussions with respect to predictions, beliefs, plans, projections, objectives, goals, assumptions of future events or performances are not statements of historical fact and may be "forward-looking statements." Forward-looking statements in this release may be identified through the use of such words as "expects", "anticipates", "estimates", "believes", or statements indicating certain actions "may", "could", or "might" occur. Actual results, performance or achievements could differ materially from those anticipated in such forward-looking statements, which involve numerous risks and uncertainties, including the Company's ability to market its products and services in a competitive environment as well as other factors.